<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences Runs NeuroScientific Study: Publishes Positive Results in Fight Against Alzheimer's

Posted by MD Biosciences on Aug 5, 2019 9:46:44 AM

View Publication Here

Our team of neuroscience specialists ran a preclinical study with NeuroScientific Biopharmaceuticals in hopes of progressing towards a human trial later in the year for Alzheimer's. Using lead drug candidate EmtinB known to stimulate the reformation of the neuronal network and restore function of damaged nerve cells, the nerve cells were successfully able to communicate again in this study. In fact, EmtinB was able to stimulate regeneration of nerve cells by more than 300% compared to the control. This is significant in affecting synapse loss, a key contributor of cognitive impairment. Together, we are paving the way for successful therapeutic treatment options for Alzheimer's. Learn about our neurodegenerative animal models, behavioral assessments and other neuroscience research services here! 

Read More

Topics: CRO/outsourcing, Neuro/CNS, preclinical research, Behavioral Research, Neuroscience, Nerve Injury, Alzheimer's

MD Biosciences Launches Neuroscience Services Website: featuring neuropathic pain, neurodegenerative disease models and electrophysiology capabilities

Posted by MD Biosciences on Jun 7, 2019 9:20:59 AM

Now live: a website dedicated to MD Biosciences' cutting-edge neurological and CNS research services offered through our Neuroscience Research Laboratories. Our facilities are fitted with state-of-the-art equipment and technologies for preclinical and translational studies, featuring clinically-relevant read outs and endpoints. Specialties include studies of neuropathic, acute and chronic pain and neurodegenerative/neuroinflammatory diseases. Unique pig translational models and electrophysiology capabilities compliment rodent capabilities and accelerate your program towards their next objectives and milestones. Contact our team today! 651-641-1770 or info@mdbiosciences.com 
Visit Neuroscience Services Website

Read More

Topics: Pain, news, Neuro/CNS, in vivo pain models, post-operative pain, Biomarkers, neuropathic pain, Neuropathy, assays, Batch Release Testing, preclinical research, translational research, Electrophysiology, Behavioral Research, porcine model, Neuroscience, Nerve Injury

New MDB Publication: Pig open field data in the PNT model for neuropathic pain

Posted by MD Biosciences on Oct 12, 2018 10:00:00 AM

We recently published a publication demonstrating the utility of open field testing in combination with behavioral scoring in the pig peripheral neuritis trauma (PNT) model for pain. Combined together and applied in this model, they represent a powerful tool to assess the spontaneous behavior of pigs in response to pain. Rodent models are often used in pain research as they offer valuable data regarding underlying mechanisms contributing to pain, though they are limited in their translatability to human application. A pivotal benefit of using pig models is their increased translatability to the clinic considering the anatomical and physiological similarities pigs share with humans in comparison to rodents. This paper suggests that pig behavioral patterns are similarly translatable. MD Biosciences is proud to be a leader in neurology-related research, offering a variety of pig studies to enhance development in multiple therapeutic areas.
 

 For more information regarding our pig study services, visit our website or contact us!

 

Read More

Topics: Pain, Stress, trauma pain, pain biomarkers, CNS imaging, Academic Researh, preclinical research, translational research, Behavioral Research, porcine model

Pig post operative pain model pioneered by our scientists recognized in a scientific publication: Synergistic Effect of Bupivacaine and Meloxicam in Clinical & Animal Studies

Posted by MD Biosciences on Jul 12, 2018 10:45:29 AM

Proud to announce that the pig post operative pain model pioneered by our scientists was used and cited in a clinical study poster publication written by Heron Therapeutics to assess the synergistic effect of Bupivacaine and Meloxicam in HTX-011.

"Meloxicam and Bupivacaine combined in a single extended-release formulation (HTX-011) delivered at the wound site in a preclinical post-surgical pain model in pigs exhibited greater analgesia than either compound delivered alone within the same extended-release formulation; this finding was confirmed in an initial clinical trial in bunionectomy" (Heron Therapeutics, 2018).

To learn more about our rodent and pig post-operative pain models, visit our preclinical pain webpage or view  our datasheet below.

pig post-operative pain (POP) model, preclinical efficacy 

Read More

Topics: Pain, post-operative pain, neuropathic pain, preclinical research

Now Available: Electrophysiology Laboratory Services featuring DANTEC Keypoint Focus

Posted by MD Biosciences on Jul 12, 2018 10:00:00 AM

 MB Biosciences is proud to announce our newly established electrophysiology capabilities suited for preclinical neuropathy research! Our lab has acquired the cutting-edge Dantec KEYPOINT Focus tool utilized to measure electrophysiological action potentials. Our scientists have applied these new capabilities in the assessment of Muscle Action Potential (measuring signals from the nerve to muscle) in rodent models of peripheral nerve injury. Using these capabilities, we can measure nerve regeneration, degeneration and protection in response to various treatments. This technology can be further applied to non-rodent species such are our pig translational pain models. Additionally, we are now offering measurement capabilities for Motor Action Potential with a specialized Renovo Neural paradigm—particularly useful for studies of EAE, MS, spinal cord injuries and CNS pain. Application of these capabilities specifically to EAE and MS models provide valuable insights into multiple areas of compound efficacy. View the graphs below to learn more about the ways in which using intraoperative techniques applied in the brain, peripheral nerve surgeries and spine has led us to developing models for monitoring impairment in neural activity. By empirically evaluating neural diseases and their physiological symptoms, we can effectively offer precise measurements for drug effect and treatment options.


To learn more about how this technology can be applied to specific study needs, please contact us.

 

In-vivo neurophysiology

 

A                                             B                                                  C

PIC1-1PIC22-1PIC33-1

Figure 1. A) CNS model - Transcranial electric motor evoked potentials (tcMEPs) were recorded from the bilateral tibialis anterior (TA) muscles using paired subdermal needle electrodes. TcMEP stimulating electrodes were placed anterior to the C3 and C4 scalp positions. B) Pain and sensory model - Somatosensory evoked potential (SSEP) - electrodes were placed along the medial aspect of each ankle at the malleoli for bipolar stimulation of the posterior tibial nerves (PTN). Somatosensory evoked potentials (SSEP) were recorded over the cerebral cortex using subdermal needle electrodes placed posterior to the C3 and C4 scalp positions. Recording electrodes were referenced to the FPz position on forehead. C) PNS model - Compound muscle action potential (CMAP) - recorded from the tibialis anterior muscle using paired subdermal needle electrodes. Stimulating electrodes were placed along the sciatic notch. Data were recorded from a Sprague Dawley rat.

   A                                              B                                            C                                               

PIC4-1PIC5-1Picture3

 

Figure 2: tcMEP Recordings from TA muscle in a multiple sclerosis model. A A healthy potential recorded from naive mouse (C57). B) Desynchronized potential recorded from a mouse treated with MOG demonstrating a clinical paralysis score of 1-2 (mild paralysis). Note multiple picks of potential, late latency for the main potential and extended duration of the total event. C) Small and weak potential recorded from a mouse treated with MOG demonstrating a clinical paralysis score of 3-4 (moderate paralysis).

Read More

Topics: Pain, neuropathic pain, preclinical research, Electrophysiology

Expanding Our Selection of Cutting-Edge CLIA and GLP Capabilities: BD LSR Fortessa™ Flow Cytometer

Posted by MD Biosciences on Jun 22, 2018 10:03:31 AM

MD Biosciences is proud to announce a recent addition to our extensive laboratory services and capabilities: The BD LSR FortessaTM X-20 Flow Cytometer offers the flexibility to support multiparametric (16+ color) analyses with advanced performance and consistency. These capabilities provide increased functionality for applications in preclinical, translational and clinical programs such as immunophenotyping of complex cellular populations, and analysis of cellular activation and proliferation states. Contact us to learn about our flow cytometry capabilities or discuss a study proposal with our scientific team! 

44
Read More

Topics: clinical research, preclinical research, translational research, Biotechnology, immunophenotyping, flow cytometry

MDB Receives 2018 Progress MN Award For Industrial & Economic Development In The Pharma & Biotech Sector Through US Minnesota-Based Site

Posted by MD Biosciences on Apr 6, 2018 10:57:40 AM

Oakdale, Minnesota USA

Nominated via the Minnesota State Dept. Of Employment and Economic Development (DEED), the Progress MN award, offered by Finance & Commerce, recognizes innovative companies that have provided major contributions to business, industrial growth and economic development in innovative and unique ways.

4FrontComplex

MD Biosciences US-site at the 4Front Technology & Office Campus in Oakdale, MN.

 

Taken from Finance and Commerce Website:

https://finance-commerce.com/2018/04/progress-mn-md-biosciences-inc/

 April 6, 2018

 

Eddie Moradian, CEO of the family-owned MD Biosciences Inc., moved to Minnesota in 2008 from Switzerland to take over the company’s American operations.

Headquartered in Switzerland, MD Biosciences operates facilities and laboratories in that country, Israel and Minnesota.

The Minnesota location provides MD Biosciences with a central location and a highly dedicated and educated pool of researchers, health care centers and universities.

The company operates early-stage drug discovery and development laboratories in Minnesota. Labs at the two other locations often participate together in collaborative or fee-for-service pharmaceutical projects, Moradian said.

On a second front, MD Biosciences works closely with pharmaceutical and clinical laboratories in developing advanced clinical diagnostic tools and research products for inflammation, neuro-inflammation, immunological and oncological disease areas.

MD Biosciences has an in-depth expertise and scientific platform that attracts “novel” drug development work in the neurological, inflammatory and oncological disease areas, he said.

Such collaborations, along with internal developments, have resulted in a pipeline of non-opioid compounds for neuropathic pain, an advanced cancer program and blood-based diagnostic tool for a specific cancer, currently in clinical trials.

In 2016, Moradian partnered with Slumberland in the creation of an advanced, multi-technological incubator in Oakdale. “Incubology” offers dry and wet laboratory space, clean rooms and office space to companies in various areas, include biomolecule production, diagnostic processes, medical devices, nanotechnology and chemical synthesis.

“We believe that Incubology will soon grow to be an important regional anchor and seeding ground for new companies and technologies,” he said, “We are truly excited about what the future may bring.”

 

 

About MD Biosciences:

MD Biosciences is a leading provider of preclinical, translational and clinical-phase contract research services.  Established in 1991, MDB provides expertise and services in areas including cancer, cardiovascular, metabolic, inflammatory and neurological conditions including pain-associated disease as well as surgical procedures. Through collaborations with pharmaceutical and medical device pioneers, MDB develops innovative therapeutics and diagnostic assays. Each scientist at MDB is highly specialized, and has an in-depth understanding of a variety of disease mechanisms and how to modulate them. This expertise, strengthened with over 10 years of pharmaceutical efficacy experience, brings value to drug development programs whether the focus is on new therapies or repositioning approved, expiring or failed therapies. Furthermore, MDB's clinical services operate at state of the art laboratories staffed with highly experienced scientists and technicians utilizing the newest and most advanced equipment available. All clinical work is performed according to CLIA standards, and may include assay development and validation, protocol design, sample archiving, and biomarker analysis services.

 

About Incubology:

Incubology was founded to bring technology start-ups together in a shared environment. Members have the benefit of dedicated lab and office space in close proximity to other entrepreneurs from diverse disciplines including biotech, pharma, device, nano and chem. With innovative thinkers from a variety of tech industries in one setting, the opportunity for shared business resources and services is a definite advantage over single-unit space. And as part of a growth-oriented campus, the possibilities for the future are endless.

www.incubology.com

 

About Finance and Commerce:

Finance and Commerce is the only daily newspaper devoted exclusively to business in the Twin Cities (MinneapolisSaint Paul) of Minnesota. Founded in 1887, it provides extensive coverage of Twin Cities business news in the areas of real estate, construction, technology, banking, energy, health care and advertising. It is the official newspaper for Hennepin County and the City of Minneapolis.

https://finance-commerce.com

 

For more information, please contact MD Biosciences at: info-us@mdbiosciences.com 

Read More

Topics: Biomarkers, drug development, clinical research, clinical diagnostics, preclinical research, translational research